chr17-7675237-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000546.6(TP53):c.376-1G>A variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000657 in 152,120 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000546.6 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152120Hom.: 0 Cov.: 33
GnomAD4 exome Data not reliable, filtered out with message: AC0;AS_VQSR AF: 0.00 AC: 0AN: 1461636Hom.: 0 Cov.: 35 AF XY: 0.00 AC XY: 0AN XY: 727092
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152120Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74296
ClinVar
Submissions by phenotype
not provided Pathogenic:3Other:1
- -
The TP53 c.376-1G>A variant disrupts a canonical splice-acceptor site and interferes with normal TP53 mRNA splicing. This variant has been reported in the published literature in individuals/families affected with breast cancer (PMIDs: 29752822 (2018), 35017683 (2022), 35886069 (2022)), rhabdomyosarcoma (PMID: 24382691 (2014)), an early glial lesion (PMID: 27501770 (2016)), and medulloblastoma (PMID: 32930885 (2021)). The frequency of this variant in the general population, 0.0000066 (1/152120 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is consistent with pathogenicity. Based on the available information, this variant is classified as pathogenic. -
- -
Observed in two children with brain tumors, one of whom also had a rhabdomyosarcoma, as well as an individual with breast cancer and a child with an adrenocortical tumor who was mosaic for the variant (Hettmer et al., 2014; Villani et al., 2016; Li et al., 2019; Pinto et al., 2021; Wang et al., 2021); Canonical splice site variant expected to result in aberrant splicing; Not observed in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 32930885, 31775759, 24382691, 11857392, 10567903, 26622941, 27489289, 30720243, 29752822, 30913944, 27501770, 35886069, 34926253, 35459788, 24700732, 27146902, 36142413, 35308232, 35791423, 20522432, 35454937, 21305319, 34675114, 33600011) -
Li-Fraumeni syndrome 1 Pathogenic:2
- -
This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. -
Hereditary cancer-predisposing syndrome Pathogenic:2
The c.376-1G>A intronic pathogenic variant results from a G to A substitution one nucleotide upstream from coding exon 4 of the TP53 gene. This alteration (referred to as IVS376-1G>A) has been reported in the germline of a 3 year old male diagnosed with anaplastic rhabdomyosarcoma (Hettmer S et al. Cancer. 2014 Apr; 120(7):1068-75). It has also been reported in an individual with a personal history of rhabdomyosarcoma at age 3, and an early glial lesion at age 11 (Villani A et al. Lancet Oncol. 2016 Sep;17:1295-305). In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein. As such, this alteration is classified as a disease-causing mutation. -
- -
Li-Fraumeni syndrome Pathogenic:1
This sequence change affects an acceptor splice site in intron 4 of the TP53 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in TP53 are known to be pathogenic (PMID: 20522432). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with clinical features of Li-Fraumeni syndrome (PMID: 21305319, 24382691, 27501770, 29752822, 32930885; internal data). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 481003). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
Ovarian neoplasm Pathogenic:1
- -
Lip and oral cavity carcinoma Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at